Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Authors
Smits, Evelien L.J.Lee, Cindy
Hardwick, Nicola R.
Brooks, Suzanne E.
Van Tendeloo, Viggo F.I.
Orchard, Kim H.
Guinn, Barbara-Ann
Affiliation
University of AntwerpIssue Date
2011-06
Metadata
Show full item recordAbstract
Immunotherapy is currently under active investigation as an adjuvant therapy to improve the overall survival of patients with acute myeloid leukaemia (AML) by eliminating residual leukaemic cells following standard therapy. The graft-versus-leukaemia effect observed following allogeneic haematopoietic stem cell transplantation has already demonstrated the significant role of immune cells in controlling AML, paving the way to further exploitation of this effect in optimized immunotherapy protocols. In this review, we discuss the current state of cellular immunotherapy as adjuvant therapy for AML, with a particular focus on new strategies and recently published results of preclinical and clinical studies. Therapeutic vaccines that are being tested in AML include whole tumour cells as an autologous source of multiple leukaemia-associated antigens (LAA) and autologous dendritic cells loaded with LAA as effective antigen-presenting cells. Furthermore, adoptive transfer of cytotoxic T cells or natural killer cells is under active investigation. Results from phase I and II trials are promising and support further investigation into the potential of cellular immunotherapeutic strategies to prevent or fight relapse in AML patients.Citation
Smits, E.L.J., Lee, C., Hardwick, N., Brooks, S.E., Van Tendeloo, V.F.I., Orchard, K., Guinn, B.A. (2011) 'Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia' Cancer immunology, immunotherapy, 60 (6):757-69Publisher
SpringerLinkPubMed ID
21519825Additional Links
http://www.springerlink.com/content/r12815u123n7x320/?MUD=MPType
ArticleLanguage
enISSN
1432-0851Sponsors
Leukaemia and Lymphoma Research, Cancer Research U.K.ae974a485f413a2113503eed53cd6c53
10.1007/s00262-011-1022-6
Scopus Count
Collections
Related articles
- Immunotherapy prospects for acute myeloid leukaemia.
- Authors: Barrett AJ, Le Blanc K
- Issue date: 2010 Aug
- Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
- Authors: Acheampong DO, Adokoh CK, Asante DB, Asiamah EA, Barnie PA, Bonsu DOM, Kyei F
- Issue date: 2018 Jan
- Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
- Authors: Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N, Barber L, Mufti GJ, Farzaneh F
- Issue date: 2009 Jun
- Immunotherapy in acute myeloid leukemia.
- Authors: Arpinati M, Curti A
- Issue date: 2014
- Recent advances in CAR-T cell therapy for acute myeloid leukaemia.
- Authors: Gao C, Li X, Xu Y, Zhang T, Zhu H, Yao D
- Issue date: 2024 May